Since Xencor’s founding in 1997, investors have been drawn to our remarkable scientific capabilities around monoclonal antibodies and solid intellectual property which serve as the engine behind our drug development programs. Currently, 11 candidates that have been engineered with Xencor's XmAb® technology are in clinical development by us or with partners. Xencor's internal programs include: XmAb®5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb®7195 in Phase 1a development for the treatment of asthma and allergic disease; XmAb14045 in Phase 1 development for acute myeloid leukemia; and XmAb13676 for B-cell malignancies and XmAb18087 for the treatment of neuroendocrine tumors, both in pre-clinical development. Our XmAb® antibody engineering platform enables us to make subtle changes to the structure of monoclonal antibodies resulting in dramatic product enhancement and market differentiation. Our XmAb technology fuels the growth of our internal pipeline and generates revenues through partnering and licensing.